Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tudorza

- PMLiVE

EMA approves GSK’s triple COPD therapy

Trelegy can now be marketed as a maintenance treatment in Europe

- PMLiVE

With US approval, GSK now needs rapid uptake for COPD triple

Aims to quickly launch the predicted blockbuster to revive its R&D portfolio

Almirall looks to crowdsource new skin health treatments

Launches open innovation platform AlmirallShare

- PMLiVE

GSK preps COPD filing for asthma pioneer Nucala

Moves despite reporting mixed data for the treatment earlier this year

- PMLiVE

Almirall appoints Peter Guenter as its CEO

He joins from Sanofi where he was executive vice president

Ron Menezes joins Almirall’s Aqua Pharmaceuticals

He joins the US dermatology group as its president and general manager

- PMLiVE

Chiesi Group’s Trimbow wins European licence

European Commission approves the COPD treatment

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

- PMLiVE

ThermiGen appoints Vladimir Paul-Blanc as president

He will also serve as the Almirall-owned firm's general manager

- PMLiVE

Almirall launches story campaign to raise rosacea awareness

The Red Girl highlights the negative psychological effects of the disease

- PMLiVE

Novartis signs ‘connected inhaler’ deal with Propeller Health

Will connect its Breezhaler devices to Propeller's digital platform

- PMLiVE

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will improve clinical trial engagement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links